Clinical trial

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

NCT06475443

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2024-06-15

PhasePHASE2

Study timeline

Study start (estimated)2024-06-15Date precision: day

Registry last updated2024-06-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Breast Cancer in the Brainunresolved

Interventions

pyrotinib plus capecitabineDRUG

Sponsors & collaborators

Henan Cancer Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06475443 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.